Is Medical Treatment Better at Lowering Bleeding-Caused Mortality than Angioplasty?

Post-discharge bleeding in patients admitted for acute coronary syndrome (ACS) is linked to higher all-cause mortality. However, this is the case for both patients who underwent angioplasty and those who were managed with medical treatment.

¿El tratamiento médico disminuye la mortalidad por sangrado vs la angioplastia?

These are interesting data, given that medical treatment is frequently preferred due to lower bleeding risk.

Speculation is based on the fact that, if the strategy were angioplasty, the bleeding would be more serious because patients would be receiving antiplatelet therapy and, if it had to be interrupted, the risk of thrombosis would also be high.

However, the prognosis for this unique population of patients with ACSs who receive medical treatment and subsequently bleed was almost unknown.

The objective of this paper recently published in J Am Coll Cardiol was to assess the association between post-discharge bleeding and mortality according to the index hospitalization strategy (angioplasty or medical treatment), and to contrast infarction vs. bleeding as a complication.


Read also: EuroPCR 2020 | Revascularization vs. Initial Medical Treatment in Chronic Patients.


A dataset of 4 large studies (APPRAISE-2, PLATO, TRACER, and TRILOGY ACS) was analyzed to establish the association between post-discharge bleeding (7 days post-ACS) and mortality.

Out of 45,011 total participants, 1,133 experienced bleeding and 2,149 died during follow-up.

The risk for mortality was significantly higher <30 days after bleeding (up to 15x higher), as well as between 30 days to 12 months (almost 3x higher) from the complication. This association between mortality and bleeding was consistent in participants treated with angioplasty or medical treatment (p for interaction = 0.240).


Read also: Virtual ACC 2020 | ISCHEMIA-CKD: Invasive Strategy vs. Medical Treatment in Higher Risk Patients.


The association between bleeding and mortality was similar to the association between infarction and mortality in both treatment strategies (p for interaction = 0.696).

Conclusion

Post-discharge bleeding in patients hospitalized for acute coronary syndrome is associated with increased all-cause mortality. Furthermore, the impact on the prognosis is similar for both treatment strategies (angioplasty vs. medical treatment). The impact on the prognosis of recurrent infarction is similar to that of bleeding.

Original Title: Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI.

Reference: Guillaume Marquis-Gravel et al. J Am Coll Cardiol 2020;76:162–71. https://doi.org/10.1016/j.jacc.2020.05.031.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...